Berlin, Germany, Dec. 19, 2013 (GLOBE NEWSWIRE) -- MagForce AG (Frankfurt, Xetra:MF6), a medical technology company that focuses on the field of oncology and is a leader in the nanotechnology sector, today announced the installation of the third NanoActivator®. The NanoActivator® was installed as part of the preparations for the new glioblastoma study at the Kiel University Hospital.
About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator® are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
For further information:
MC Services AG
T +49 211 529252 22
F +49 211 529252 29
M +49 151 12 555 759
MagForce_Press Release_December 19, 2013 http://hugin.info/143761/R/1751288/590311.pdf